퓨쳐켐
Financials
Valuation Metrics
퓨쳐켐's Market Cap is ₩1370B. At end of 2025 it was ₩6697B. Ranked #1075 of 2,421 in KR market (top 44%), #554 of 1,640 on KOSDAQ (top 34%), #123 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 137.03B KRW | KR#1,075/2,421 Sec#123/231 |
| Revenue | 20.59B KRW | KR#2,129/2,421 Sec#154/231 |
| Net Income | -11.09B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 68.41B KRW | KR#2,026/2,421 Sec#168/231 |
| Net Assets | 55.11B KRW | KR#1,842/2,421 Sec#155/231 |
| Employees | 87 | KR#1,750/2,421 Sec#139/231 |
| Value | ||
| P/B | 2.49x | KR#2,038/2,421 Sec#157/231 |
| P/S | 6.66x | KR#2,210/2,421 Sec#150/231 |
| FCF Yield | -1.80% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -20.12% | KR#2,095/2,421 Sec#162/231 |
| ROA | -16.21% | KR#2,206/2,421 Sec#169/231 |
| Op. Margin | -45.52% | KR#2,225/2,421 Sec#159/231 |
| Revenue Growth | 7.55% | KR#1,044/2,421 Sec#99/231 |
| Financial Health | ||
| Debt Ratio | 24.14% | KR#470/2,421 Sec#56/231 |
| Total Debt | 4.33B KRW | KR#1,812/2,421 Sec#175/231 |
| FCF | -2.47B KRW | KR#1,367/2,421 Sec#104/231 |
| Cash | 5.77B KRW | KR#1,959/2,421 Sec#177/231 |
| Current Ratio | 3.34x | KR#492/2,421 Sec#72/231 |
| Performance | ||
| 1Y Return | -66.37% | KR#2,276/2,421 Sec#216/231 |
| 1M Return | -17.43% | KR#2,281/2,421 Sec#203/231 |
| From 52W High | -81.99% | KR#2,362/2,421 Sec#223/231 |
| 1Y MDD | -81.54% | KR#2,323/2,421 Sec#217/231 |
| Trading | ||
| Volume | 124,008 shares | KR#687/2,421 Sec#61/231 |
| Trading Value | 761.5M KRW | KR#803/2,421 Sec#83/231 |
| Foreign Own. | 6.17% | KR#717/2,421 Sec#64/231 |
| Per Share | ||
| EPS | -494 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,457 KRW | KR#1,964/2,421 Sec#156/231 |
Company Info
FutureChem, a listed corporation, was established in 2001 to manufacture and sell radiopharmaceutical precursors, transferring its listing to the KOSDAQ Market in 2016 after a KONEX Market listing in 2015. The company develops, produces, and sells new radiopharmaceutical drugs, precursors, synthetic reagents, and automated synthesis devices, holding various pipelines including Alzavue for Alzheimer's diagnosis. Its affiliates are FutureChem Healthcare, SI Healthcare, and FutureChem U.S.A. FutureChem is headquartered in Seongdong-gu, Seoul.